NEW YORK (GenomeWeb) –Lucigen said today that it has signed a global agreement with Illumina for Lucigen to be the sole distributor of Epicentre Technologies' genomics kits, enzymes, and ancillary reagents.
Products covered by the new agreement are in addition to select Epicentre products that were licensed and transferred to Lucigen for manufacture and distribution in December, the company said.
Lucigen, based in Madison, Wisconsin, manufactures and supplies products for synthetic biology, next-generation sequencing, genetic amplification, and protein expression research.
Epicentre was acquired by Illumina in 2011, and is known for its genomics and transcriptomics products for gene expression, cloning, and in vitro transcription.